Background. This study used case reports to review the role of systemic chemotherapy in oligometastatic colorectal cancer (CRC) and to suggest ways to integrate clinical research findings into the interdisciplinary management of this potentially curable subset of patients. Methods. This educational review discusses the role of chemotherapy in the management of oligometastatic metastatic CRC. Results. In initially resectable oligometastatic CRC, the goal of chemotherapy is to eradicate micrometastatic disease. Perioperative 5-fluorouracil and oxaliplatin together with surgical resection can result in 5-year survival rates as high as 57 %. With the development of increasingly successful chemotherapy regimens, attention is being paid to chemotherapy used to convert patients with initially unresectable metastasis to patients with a chance of surgical cure. The choice of chemotherapy regimen requires consideration of the goals for therapy and assessment of both tumor-and patient-specific factors. Conclusion. This report discusses the choice and timing of chemotherapy in patients with initially resectable and borderline resectable metastatic CRC. Coordinated multidisciplinary care of such patients can optimize survival outcomes and result in cure for patients with this otherwise lethal disease.
Given the prevalence of this disease and the associated mortality, optimizing therapy for patients with metastatic disease is critical.
In the era before effective systemic therapy, patients with metastatic CRC achieved a median survival time of approximately 6 months. 2 Subsequent advances in systemic therapy increased the median overall survival (OS) time for these patients to longer than 24 months. 3 In a similar time frame, advances in surgery led to identification of a subset of metastatic CRC patients whose outcomes are markedly improved with surgical intervention. This distinct clinical state in which macroscopic disease is confined to a limited and potentially resectable anatomic distribution is referred to as oligometastatic CRC. 4 However, due to a high likelihood of occult micrometastatic disease, integrating chemotherapy with surgical extirpation of macroscopic disease is crucial. For patients who undergo such therapy, median OS rates in the range of 5 years and a distinct chance for cure can be expected. 5, 6 This report uses case presentations to highlight clinical trials that have advanced our understanding of the role of systemic chemotherapy in oligometastatic CRC and to suggest ways to integrate these clinical trial findings into the interdisciplinary management of patients with oligometastatic CRC.
CASE 1
A 46-year-old man presents with several weeks of low abdominal pain and hematochezia. Colonoscopy demonstrates a mass near the splenic flexure, and biopsy confirms moderately differentiated adenocarcinoma. Staging studies demonstrate a solitary 5-cm mass in segment 6 of the liver (Fig. 1) . The carcinoembryonic antigen (CEA) level is 39.8 ng/mL. How should this patient be approached?
About 10-20 % of patients with liver metastases from CRC are considered resectable with curative intent. 7, 8 The 5-year survival rates in large series of patients with complete resection alone range from 28 to 47 %. 5, [9] [10] [11] The number of metastases is no longer a deciding factor, but rather whether negative surgical margins can be obtained with at least 30 % of remaining healthy liver mass. 12, 13 One option is initial surgical resection consisting of extended left colectomy and synchronous liver resection. The extent of the liver resection depends on the relationship of the metastases to the hepatic vein and portal pedicle. If a right hepatectomy is required to achieve negative margins, then it is important for the surgeon to determine whether the residual liver volume is adequate. Excellent resources have been developed to calculate liver volumetry either manually or using three-dimensional (3D) modeling software. Normally, 25 % residual liver volume is adequate, but for patients who undergo extensive systemic chemotherapy, often 40 % is deemed appropriate. If residual liver volume is deemed to be inadequate, then portal vein embolization is one option. The other option is consideration of preoperative systemic chemotherapy to decrease the size of the liver metastases.
In the reported case, the primary tumor and liver metastases are amenable to complete resection without involved margins (R0 resection), leaving an adequate volume of residual liver. However, with synchronous CRC liver metastasis, undetected micrometastatic disease is a significant risk. Thus, the first question to be addressed is whether to proceed immediately with surgical resection or to treat the patient first with neoadjuvant chemotherapy.
Neoadjuvant systemic therapy has multiple theoretical advantages over primary surgical resection of oligometastatic CRC. One potential advantage is that it allows for early administration of agents with ability to eradicate micrometastatic disease when the likelihood of such occult disease is high. Other potential advantages include the ability to reduce the volume of macroscopic disease requiring resection and the ability to assess response as an in vivo test of chemotherapeutic sensitivity to inform future treatment decision making. 14, 15 The potential disadvantages of neoadjuvant therapy include toxicity that hampers the outcome from subsequent surgical resection and the possibility that tumor progression with treatment precludes future surgery. [16] [17] [18] Nonetheless, the presence of primary chemotherapy-refractory disease is uncommon and a stronger predictor of poor outcome than the sequence of therapy itself. 19 In this report, we address perioperative chemotherapy and adjuvant chemotherapy approaches sequentially.
Perioperative Chemotherapy
The landmark European Intergroup EORTC 40983/ EPOC trial originally published in 2008 is perhaps the most robust clinical trial data set in the resectable oligometastatic setting. 20 In this trial, 364 patients with CRC and up to four liver metastases were assigned to surgery alone or to six cycles of the FOLFOX4 regimen consisting of oxaliplatin, leucovorin, bolus, and short-term infusional 5-fluorouracil (5-FU) both before and after surgery. The study was powered to detect a 40 % increase in progression-free survival (PFS).
The primary analysis of all randomly assigned patients showed a trend toward increased PFS among patients assigned to perioperative chemotherapy, with a hazard ratio (HR) of 0.79 [95 % confidence interval (CI) 0.62-1.02; p = 0.058]. The median PFS increased from 11.7 to 18.7 months. The sensitivity analyses, the patients deemed eligible for surgery and those who proceeded to surgical resection exhibited a significant increase in PFS, with respective HRs of 0.77 (95 % CI 0.6-1.00; p = 0.041) and 0.73 (95 % CI 0.55-0.97; p = 0.025). Only 12 of the 171 patients receiving preoperative chemotherapy progressed (7 %), and of those, only eight did not undergo surgical resection. The overall operative mortality was less than 1 % in both treatment groups. An updated survival analysis did not detect a statistically significant difference in OS between the groups (HR 0.88; p = 0.34). However, the study was not designed or powered to detect a difference in OS. 21 Nonetheless, a posteriori calculations suggested that a 33 % or greater improvement in survival with perioperative chemotherapy could have been detected with 80 % power. 21 Several limitations of EORTC 40983 warrant attention. The control group did not receive adjuvant chemotherapy. Therefore, the results do not provide direct evidence that the perioperative strategy is superior to an adjuvant approach. Only 63 % of the patients in the perioperative group started the postsurgical period of chemotherapy. Although EORTC 40983 is the largest controlled study in this setting, it was not adequately powered to detect clinically meaningful OS differences between the study arms. A further limitation was that patients with more than four liver metastases were not included. Notwithstanding these limitations, this study provides the strongest evidence to date that a perioperative chemotherapy approach is safe and can improve outcomes for patients with oligometastatic CRC.
To date, no regimen has been proved superior to FOL-FOX for initially resectable patients, although the addition of bevacizumab to capecitabine and oxaliplatin (XELOX) was demonstrated to be safe in a phase 2 study. 22 Moreover, a cautionary signal was raised by the initial results of the New EPOC study comparing FOLFOX with or without cetuximab in resectable oligometastatic CRC. 23 Although the response with FOLFOX plus cetuximab was superior (70 vs. 62 %), PFS was significantly inferior to that of FOLFOX alone (14.8 vs. 20.5 months; p \ 0.030).
Adjuvant Chemotherapy
In the 5-FU era, the FFCD ACHBTH AURC 9002 24 and the EORTC/NCIC/GIVIO [ENG] 25 randomized phase 3 trials were designed to address the issue of adjuvant chemotherapy after resection of limited liver and/or lung metastases. Unfortunately, each trial failed to meet its accrual goal and was closed early. Because both trials were of similar design and used similar bolus 5-FU and leucovorin regimens, a pooled analysis was performed. 26 Of the 278 patients, 138 were assigned to adjuvant chemotherapy and 140 patients to surgery alone. The inclusion criteria required resection of the primary tumor and four or fewer metastases located at a single site (liver in the FFCD trial and liver or lung in the ENG trial).
In the pooled analysis, the median disease-free survival (DFS) period was 18.8 months for those assigned to surgery alone and 27.9 months for those assigned to adjuvant chemotherapy (HR 1.32; 95 % CI 1.00-1.76; p = 0.058). The corresponding median OS was 47.3 months compared with 62.2 months (HR 1.32; 95 % CI 0.95-1.82; p = 0.095).
In the multivariate analysis, the risks of recurrence (HR 1.39; p = 0.02) and death (HR 1.39; p = 0.046) were significantly greater among the patients assigned to surgery alone than among those assigned to chemotherapy. Despite the inherent limitations of an underpowered, pooled analysis, these data suggest a benefit for adjuvant 5-FU-based chemotherapy.
In the oxaliplatin era, no completed phase 3 trials evaluated the benefit of adjuvant oxaliplatin-based chemotherapy versus surgery alone in the oligometastatic setting. A retrospective analysis of 60 patients suggested an improvement in DFS and OS compared with historical controls. 27 A strong argument can be made for extrapolation of data from the stage 3 adjuvant CRC experience to the oligometastatic setting because the goal of eradicating micrometastatic disease is identical. Phase 3 data supporting adjuvant chemotherapy with either 5-FU or 5-FU combined with oxaliplatin in stage 3 CRC is robust. 28, 29 The additional utility of irinotecan added to 5-FU was prospectively studied in the oligometastatic setting. The CPT-GMA-301 trial randomized 306 patients after R0 resection of oligometastatic hepatic metastasis to adjuvant bolus and short-term infusional 5-FU and leucovorin (LV5FU2) or the same regimen with irinotecan (FOL-FIRI). 30 The median DFS for the patients receiving LV5FU2 was 21.6 months compared with 24.7 months for the patients receiving FOLFIRI (HR 0.89; p = 0.44). No OS advantage was observed with the addition of irinotecan to LV5FU2 therapy. Interestingly, the lack of benefit from irinotecan in the oligometastatic setting mirrors the results of trials involving stage 3 CRC, with multiple studies failing to demonstrate a benefit from adjuvant irinotecan. [31] [32] [33] Similarly, no prospective data support the addition of bevacizumab, cetuximab, or panitumumab to adjuvant chemotherapy in resected CRC.
Given the theoretical benefits from early eradication of micrometastatic disease, the ability to assess chemotherapy sensitivity in vivo, and the absence of data to suggest inferior surgical outcomes with neoadjuvant chemotherapy, we generally recommend perioperative chemotherapy with FOLFOX in cases such as the reported case. Progression during preoperative chemotherapy is uncommon, reflects a poor disease biology, and necessities consideration of alternative treatment options to offer a chance of prolonged remission. 19 However, support exists for the use of adjuvant therapy in resected oligometastatic CRC for patients with good functional status and prolonged life expectancy. An adjuvant approach may be preferred for selected patients who may gain less from early systemic therapy, such as those with very small solitary tumors or an isolated metachronous recurrence. 34 Close cooperation between the treating medical oncologist and surgeon is essential to optimize the timing of therapy.
CASE 2
A 67-year-old man is referred from a regional community hospital with a large right liver metastases and a history of a right hemicolectomy for stage 2 cecal adenocarcinoma. A computed tomography (CT) scan of the liver demonstrates a large right lobe metastases extended to the caudate lobe in close proximity to the inferior vena cava (Fig. 1) . It is determined that the lesion cannot be resected with a high probability of negative margins. How should such a case be approached?
A subset of metastatic CRC patients presents with disease that is not initially resectable, with high probability of negative margins, but for whom a good response to therapy can render all sites of disease resectable. ''Conversion therapy'' is defined as treatment intended to convert initially unresectable disease to resectable disease. The potential benefit of conversion therapy was illustrated in a prospective study in which a cure was obtained for 16 % of patients with initially unresectable colorectal liver metastases who had 5-and 10-year survival rates of 33 and 27 % respectively. 35 Even in the absence of cure, conversion to resection defines a subgroup of patients with survival rates superior to those of patients who do not undergo resection, whose 5-year survival with chemotherapy alone is only about 10 %. 36 Despite published guidelines, 37, 38 the specific definition of unresectable metastatic CRC amenable to conversion therapy is evolving. Nonetheless, the goals of conversion chemotherapy are uniform: to reduce tumor volume (overall response rate) while simultaneously avoiding endorgan (particularly liver) toxicity that results in increased surgical morbidity and mortality. 36 
Conversion Therapy
Reported response rates with modern chemotherapy regimens vary (Table 1) . Standard doublet regimens NS not significant, EGFR epidermal growth factor receptor (FOLFOX and FOLFIRI) have frontline response rates ranging from 34 to 56 % and are considered equivalent. [39] [40] [41] [42] [43] [44] The response rate induced by the triplet regimen FOLFOXIRI that includes leucovorin, fluorouracil, oxaliplatin, and irinotecan is superior to that of FOLFIRI (66 vs. 41 %; p \ 0.0001), 41 and the regimen is associated with conversion to resectability in 19 % of patients. 45 The addition of biologic agents to a cytotoxic chemotherapy backbone in advanced CRC is the subject of active research. The ability of bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, to increase PFS and OS with modern chemotherapy in the metastatic setting is established. However, its ability to increase the response rate is the subject of debate. In the frontline setting, bevacizumab improved response when combined with a bolus 5-FU, leucovorin, and irinotecan regimen (IFL) ( Table 1) . 39, 46 However, no such improvement in response was observed in the large N016966 trial of FOLFOX/ XELOX with or without bevacizumab. 47 These results raise questions about the utility of this agent in the conversion setting with response as the primary goal. 47 The response data for the use of monoclonal anti-epidermal growth factor receptor (EGFR) antibodies (cetuximab or panitumumab) are more uniform. The addition of cetuximab or panitumumab to common frontline chemotherapy regimens consistently increases the response rate, specifically in KRAS codon 12 and 13 wild type tumors (Table 1) . 43, [48] [49] [50] The potential benefit in the conversion setting also has been demonstrated in a phase 2 study, in which R0 resections were achieved in 34 % of initially unresectable patients treated with neoadjuvant FOLFOX or FOLFIRI and cetuximab. 51 In the CRYSTAL trial, which compared FOLFIRI with and without cetuximab, the R0 resection rate for KRAS wild-type tumors was higher in the cetuximab arm of the study (5.1 vs. 2.0 %; p = 0.027). 52 Recently, the observation that anti-EGFR antibody therapy is ineffective for KRAS codon 12 and 13 mutated tumors has been extended to mutations in KRAS codons 59, 61, 117, and 146 as well as similar locations in NRAS. [53] [54] [55] Currently, for patients with mutation at any of these sites, the use of an alternative regimen such as FOLFOXIRI is indicated. However, predictive biomarker development for selection of EGFR-targeted therapy is an area of active investigation, with resultant dynamic changes in our understanding of the utility of these markers. Therefore, future refinements to this selection strategy are expected.
Several attempts have been made to enhance delivery of chemotherapy to the liver using hepatic arterial infusion (HAI). Indeed, several single-institution studies have demonstrated the potential for the efficacy of this approach. 56, 57 However, due to the potential for serious liver toxicity and the expertise required for successful administration, HAI chemotherapy cannot currently be recommended outside select experienced centers.
Although a secondary goal of systemic therapy in the conversion setting is to avoid end-organ toxicity, all active cytotoxic agents in CRC are associated with some hepatotoxicity. Prolonged 5-FU administration is associated with hepatic steatosis and increased surgical morbidity. 58, 59 Oxaliplatin also can increase surgical morbidity and is associated with hepatic sinusoidal obstruction syndrome. [59] [60] [61] [62] Irinotecan toxicity is perhaps the most worrisome due to the potential for increased surgical morbidity and mortality from reduced hepatic reserve and nonalcoholic steatohepatitis. 18, 59, [62] [63] [64] Because the complication rate associated with hepatectomy is related to the number of chemotherapy cycles administered, 65 the number of presurgical cycles of therapy should be considered carefully.
Overall, for the patient with initially unresectable oligometastatic CRC amenable to conversion therapy, the best chemotherapy or chemotherapy-biologic combination is not established. Furthermore, the optimal duration of preoperative or total systemic therapy also is unclear. Given   FIG. 2 Suggested treatment algorithm for a patient with oligometastatic colorectal cancer the high response rate and reasonable tolerability, we currently favor the FOLFOXIRI regimen for patients with a good functional status regardless of RAS tumor status. A regimen containing an EGFR inhibitor may be a reasonable alternative for pan-RAS wild-type tumors. However, the New EPOC results suggest caution and imply that the chemotherapy backbone should not contain oxaliplatin. 23 To limit chemotherapy-induced hepatotoxicity and surgical morbidity and mortality, we favor the fewest cycles of preoperative chemotherapy to attain an adequate response, particularly when irinotecan is used. Our algorithm for approaching patients with oligometastatic CRC is presented in Fig. 2 .
CONCLUSION
It is an exciting time to be treating CRC because outcomes have improved dramatically in the last several decades. An interdisciplinary approach to oligometastatic colorectal metastases, as described in this review, can improve outcomes in this potentially curable subgroup.
